226 related articles for article (PubMed ID: 16127890)
1. The role of the drug formulary in a valve-based pharmacy benefit.
Giaquinta D
Manag Care Interface; 2005 Aug; 18(8):37-8. PubMed ID: 16127890
[No Abstract] [Full Text] [Related]
2. Targeting formulary pull-through strategies: the role of pharmaceutical manufacturers.
Navarro RP
Manag Care Interface; 1999 May; 12(5):84-6. PubMed ID: 10537482
[No Abstract] [Full Text] [Related]
3. Do P&T committees have enough power? Plans and PBMs are divided about sharing drug prices with clinicians. Is it better to have an administrative committee determine the formulary?
Cross M
Manag Care; 2007 Apr; 16(4):39-42. PubMed ID: 17491288
[No Abstract] [Full Text] [Related]
4. Pharmaceuticals issue brief: managed care drug formularies: year end report-2003.
MacEachern L
Issue Brief Health Policy Track Serv; 2003 Dec; ():1-8. PubMed ID: 14969259
[TBL] [Abstract][Full Text] [Related]
5. Working with PBMs (pharmacy benefit managers).
Peterson C
Healthplan; 1999; 40(2):83-6, 88-9. PubMed ID: 10537477
[No Abstract] [Full Text] [Related]
6. Pharmacy benefit management as a quality safeguard.
Giaquinta D
Manag Care Interface; 2002 Mar; 15(3):54, 57. PubMed ID: 11925680
[No Abstract] [Full Text] [Related]
7. Reinventing the PBM (pharmacy benefit manager).
Marcille JA; Wynn P
Manag Care; 1997 Apr; 6(4):64-6, 75-8. PubMed ID: 10167003
[No Abstract] [Full Text] [Related]
8. Ethical, practical, and business considerations in pharmacy benefit design.
Penna P
Manag Care Interface; 2000 Jun; 13(6):64, 66-7. PubMed ID: 11183016
[No Abstract] [Full Text] [Related]
9. Influencing drug formulary and contract performance.
Navarro RP
Manag Care Interface; 1999 Apr; 12(4):89-91, 96. PubMed ID: 10387398
[No Abstract] [Full Text] [Related]
10. The ripple effects of a restrictive Medicaid formulary.
Grabowski H
Am J Manag Care; 2003 Oct; 9(10):648-9. PubMed ID: 14572174
[No Abstract] [Full Text] [Related]
11. Managed care pharmacy 101: learning from the students.
Penna P
Manag Care Interface; 2005 Apr; 18(4):28, 31. PubMed ID: 15889760
[No Abstract] [Full Text] [Related]
12. Medicare formulary model seen by many as too inclusive.
Carroll J
Manag Care; 2004 Nov; 13(11):10, 12. PubMed ID: 15595394
[No Abstract] [Full Text] [Related]
13. Benefit and formulary options appear in specialty pharmacy. Management tactic borrowed from traditional pharmacy.
Reinke T
Manag Care; 2014 Jan; 23(1):7-8. PubMed ID: 24772498
[No Abstract] [Full Text] [Related]
14. Pharmaceutical formularies: the right formula for cost and utilization?
Austin B
Find Brief; 2004 Aug; 7(5):1-3. PubMed ID: 15298009
[No Abstract] [Full Text] [Related]
15. The effect of the Medicare Part D benefit on medication management.
Pezalla E
Manag Care Interface; 2007 Jul; 20(7):13, 15. PubMed ID: 17849727
[No Abstract] [Full Text] [Related]
16. Next wave of change in managed health care will sweep away antiquated prescription practices.
Weishar G
Health Care Innov; 1997; 7(1):8-13. PubMed ID: 10165129
[No Abstract] [Full Text] [Related]
17. Use of multitier benefit designs increases.
Manag Care; 2008 Nov; 17(11):43. PubMed ID: 19051999
[No Abstract] [Full Text] [Related]
18. The case for a value-based formulary: striving for total lowest net cost.
Weart W; Bauman GR
Manag Care Interface; 2007 Apr; 20(4):42-7. PubMed ID: 17474330
[TBL] [Abstract][Full Text] [Related]
19. Use of health-related quality of life information in managed care formulary decision-making.
Wu WK; Sause RB; Zacker C
Res Social Adm Pharm; 2005 Dec; 1(4):579-98. PubMed ID: 17138497
[TBL] [Abstract][Full Text] [Related]
20. Bad tiered formulary designs yield poor outcomes, high cost.
Sipkoff M
Manag Care; 2004 Aug; 13(8):27, 31-2, 34-5. PubMed ID: 15457893
[No Abstract] [Full Text] [Related]
[Next] [New Search]
